An Evaluation of the Pharmacokinetics of a Single Dose of Daptomycin (4 mg/kg) in Pediatric Patients Aged Two to Seventeen Years Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-positive Infection
Latest Information Update: 13 Dec 2023
At a glance
- Drugs Daptomycin (Primary)
- Indications Gram-positive infections
- Focus Pharmacokinetics
- Sponsors Cubist Pharmaceuticals
- 19 Jan 2007 Status changed from in progress
- 22 Aug 2006 Status change
- 26 Nov 2005 New trial record.